A generic alternative indicated for Oncology Support. This treatment affects immune system signaling markers, assisting the body in mitigating abnormal cellular proliferation.
Indicated to manage specific blood cancers by addressing immune cell function to support disease remission and mitigate the growth of malignant cells effectively.
Mechanism of Action
Lenalidomide targets cancer cells directly and changes the immune environment. It helps the body's immune system recognize and kill cancer cells while also cutting off the blood supply tumors need to survive.
Route of Administration
Oral
Onset Time
Steady state in 2 days; weeks for response
Duration
24 hours
Contraindications
Pregnancy, Known hypersensitivity to lenalidomide, Women of childbearing potential (without strict REMS adherence)
Severe Adverse Events
Severe birth defects, Deep vein thrombosis, Pulmonary embolism, Severe bone marrow suppression, Severe skin reactions (SJS), Tumor lysis syndrome
Common Side Effects
Fatigue, Rash, Mild itching
Uncommon Side Effects
Diarrhea, Constipation, Nausea, Low white blood cell count, Peripheral edema
Information for Lenalidomide is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
